DIABETIC MACULAR EDEMA AND CATARACT SURGERY: Phacoemulsification Combined With Dexamethasone Intravitreal Implant Compared With Standard Phacoemulsification

Claudio Furino, Francesco Boscia, Alfredo Niro, Maria D'Addario, Maria O Grassi, Valeria Saglimbene, Michele Reibaldi, Giovanni Alessio, Claudio Furino, Francesco Boscia, Alfredo Niro, Maria D'Addario, Maria O Grassi, Valeria Saglimbene, Michele Reibaldi, Giovanni Alessio

Abstract

Purpose: To compare functional and anatomical results of combined phacoemulsification and dexamethasone intravitreal implant (Ozurdex; DEX-I) with standard phacoemulsification in diabetic patients with cataract.

Methods: Retrospective, comparative, cohort study. Patients with nonproliferative diabetic retinopathy, macular edema, and cataract, treated routinely at the Eye Clinic, Azienda Ospedaliero Universitaria Policlinico, Bari, Italy with phacoemulsification associated with DEX-I (n = 23; Phaco-Dex) or standard phacoemulsification (n = 23; Phaco-alone). Best-correct visual acuity, central subfield thickness, and intraocular pressure were assessed at baseline and monthly for 3 months after surgery, and t-test was used to assess change from baseline. A multilevel regression model with an unstructured correlation-type matrix to account for repeated data measures was used for statistical analysis in and between groups.

Results: With Phaco-Dex, best-correct visual acuity increased significantly from the first month (P = 0.0005 vs. baseline) and remained stable at the following visits; central subfield thickness decreased significantly from Month 2 (P = 0.049 and P = 0.04 vs. baseline, respectively); at each timepoint, central subfield thickness was significantly lower in the Phaco-Dex group versus Phaco-alone. Intraocular pressure increased significantly during follow-up (P = 0.001 at Month 3 vs. baseline) but remained within the normal range. In the Phaco-alone group, best-correct visual acuity, and intraocular pressure did not show any significant changes after surgery, whereas central subfield thickness increased from Month 2 (P = 0.05 vs. baseline).

Conclusion: In diabetic patients with macular edema and visually significant cataract, combined treatment with phacoemulsification and DEX-I seemed to be effective, safe, and superior to standard phacoemulsification considering both functional and tomographic parameters.

Conflict of interest statement

None of the authors has any financial/conflicting interests to disclose.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.

Figures

Fig. 1.
Fig. 1.
Change in BCVA over time. Phaco, phacoemulsification.
Fig. 2.
Fig. 2.
Change in CST over time. Phaco, phacoemulsification.
Fig. 3.
Fig. 3.
Change in IOP over time. Phaco, phacoemulsification.

References

    1. Badhania M. A review: cataract, a common ocular complication in diabetes. Int J Pharmacol Res 2016;6:189–194.
    1. Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res 2008;3:52–65.
    1. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol 2010;2010:608751.
    1. Bernth-Petersen P, Bach E. Epidemiologic aspects of cataract surgery. III: frequencies of diabetes and glaucoma in a cataract population. Acta Ophthalmol (Copenh) 1983;61:406–416.
    1. Zhang X, Zeng H, Bao S, et al. . Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014;4:27.
    1. Solomon SD, Chew E, Duh EJ, et al. . Diabetic retinopathy: a position statement by the American diabetes association. Diabetes Care 2017;40:412–418.
    1. Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology 2000;107:457–462.
    1. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007;114:881–889.
    1. Greenberg PB, Havnaer A, Oetting TA, Garcia-Ferrer FJ. Cataract surgery practice patterns in the United States Veterans Health Administration. J Cataract Refract Surg 2012;38:705–709.
    1. Wong TY, Sun J, Kawasaki R, et al. . Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 2018;125:1608–1622.
    1. Shah TJ, Conway MD, Peyman GA. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy. Clin Ophthalmol 2018;12:2223–2235.
    1. Boyer DS, Yoon YH, Belfort R, Jr, et al. . Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904–1914.
    1. Denniston AK, Chakravarthy U, Zhu H, et al. . The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) users group, report 2: real-world data for the impact of cataract surgery on diabetic macular oedema. Br J Ophthalmol 2017;101:1673–1678.
    1. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259–266.
    1. Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis 2015;6:234–245.
    1. Ozurdex. Summary of product characteristics. Available at: .
    1. Boyer DS, Faber D, Gupta S, et al. . Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (Philadelphia, Pa) 2011;31:915–923.
    1. Callanan DG, Gupta S, Boyer DS, et al. . Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843–1851.
    1. Callanan DG, Loewenstein A, Patel SS, et al. . A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017;255:463–473.
    1. Chatziralli I, Theodossiadis P, Parikakis E, et al. . Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 2017;8:1393–1404.
    1. Fraser-Bell S, Lim LL, Campain A, et al. . Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology 2016;123:1399–1401.
    1. Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 2011;5:1613–1621.
    1. Mishra SK, Gupta A, Patyal S, et al. . Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous 2018;4:13.
    1. Poornachandra B, Kumar VBM, Jayadev C, et al. . Immortal ozurdex: a 10-month follow-up of an intralenticular implant. Indian J Ophthalmol 2017;65:255–257.
    1. Scaramuzzi M, Querques G, Spina CL, et al. . Repeated intravitreal dexamethasone implant (ozurdex) for diabetic macular edema. Retina (Philadelphia, Pa) 2015;35:1216–1222.
    1. Tservakis I, Koutsandrea C, Papaconstantinou D, et al. . Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors. Curr Drug Saf 2015;10:145–151.
    1. Agarwal A, Gupta V, Ram J, Gupta A. Dexamethasone intravitreal implant during phacoemulsification. Ophthalmology 2013;120:211–215.
    1. Furino C, Boscia F, Niro A, et al. . Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex(R)) in diabetic patients with coexisting cataract and diabetic macular edema. J Ophthalmol 2017;2017:4896036.
    1. Panozzo GA, Gusson E, Panozzo G, Dalla Mura G. Dexamethasone intravitreal implant at the time of cataract surgery in eyes with diabetic macular edema. Eur J Ophthalmol 2017;27:433–437.
    1. Calvo P, Ferreras A, Al Adel F, et al. . Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery. Retina (Philadelphia, Pa) 2018;38:490–496.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться